胸腺肽治疗低病毒载量的HBeAg阴性慢性乙型肝炎的随机对照研究  

Thymosin treatment of HBeAg-negative chronic hepatitis B patients with low viral load: a randomized controlled study

作　　者：闵筱辉[1] 刘婷[1] 张立伐[1] 

机构地区：[1]中山大学孙逸仙纪念医院感染科,广东广州510120

出　　处：《热带医学杂志》2013年第9期1089-1091,共3页Journal of Tropical Medicine

基　　金：广东省科技计划项目(2012B031800078)

摘　　要：目的探讨胸腺肽肠溶片治疗低病毒载量的HBeAg阴性慢性乙型肝炎的临床疗效。方法按随机对照原则选择85例HBV DNA阳性但小于104copies/ml、HBeAg阴性的慢性乙型肝炎患者,随机分入胸腺肽组(n=41)和对照组(n=44),观察两组在血清丙氨酸转氨酶(ALT)和HBV DNA阴转率等方面的差别。结果治疗12、24周时,胸腺肽组HBV DNA阴转率分别为43.9%(18/41)和61.0%(25/41),明显高于对照组的15.9%(7/44)和15.9%(7/44)(P<0.05)。停药24周后,胸腺肽组HBV DNA阴转率仍保持在48.8%(20/41),优于对照组的11.4%(5/44)(P<0.05)。治疗过程中,胸腺肽组的ALT水平在治疗24周以及停药后24周分别为(28.3±9.6)U/L和(31.7±10.5)U/L,低于对照组的(39.3±11.2)U/L和(40.1±10.9)U/L,差异有统计学意义(P<0.05)。结论胸腺肽肠溶片治疗低病毒载量的e抗原阴性慢性乙型肝炎可取得较高的HBV DNA阴转率,改善肝功能,同时也能明显降低该类患者对长期抗病毒治疗的需要。Objective To evaluate the clinical efficacy of thymosin enteric-coated tablets in the treatment of HBeAg-negative chronic hepatitis B patients with low viral load. Method Eighty-five HBeAg-negative chronic hepatitis B patients, with less than 104 copies/ml of HBV DNA, were randomly divided into two groups： control group and the thymosin treatment group treated with thymosin enteric-coated tablets. The level of serum alanine aminotransferase （ALT） and negative rate of HBV DNA between the two groups were determined at the zero, 12^th, 244 and 484 week. Results At the 124 and 244 week after treatment, the negative conversion rate was 43.9% （18/41） and 61.0% （25/41）, respectively. The result was significantly higher than the control group 15.9% （12^th week） and 15.9% （24^th week） （P〈0.05）. At the 244 week after the treatment withdrawal, the negative conversion rate in the thymosin treatment group （48.8%, 20/41 ） was higher than the control group （11.4%, 5/44, P〈0.05）. The level of ALT in the thymosin group at the 24^th week and 24^th week after treatment withdrawal was （28.3 ± 9.6）U/L and （31.7± 10.5）U/L, respectively, and that of the control group was （39.3 ± 11.2）U/L and （40.1± 10.9）U/L, respectively. The level of ALT in the thymosin group was significantly lower than the control group （P〈0.05）. Conclusion Thymosin enteric-coated tablets can increase the negative conversion rate of HBV DNA and decrease the level of ALT in HBeAg-negative chronic hepatitis B patients with low viral load. At the same time, it can significantly reduce the needs of these patients for long-term antiviral therapy.

关 键 词：乙型病毒性肝炎 低病毒载量 胸腺肽 HBEAG阴性 

分 类 号：R512.62[医药卫生—内科学]